Study on ATRA and Carfilzomib for Patients with Multiple Myeloma

Inclusion Criteria

• Adults aged 18 or older with multiple myeloma that has returned or not responded to treatment.
• Previously treated with at least three different therapies, including Carfilzomib, and did not respond after two cycles or relapsed during treatment.
• Able to understand and sign a consent form.
• In good general health, with a performance status score of 0 to 2.
• Have adequate organ function, including:
  • Hemoglobin level of at least 8 g/dL.
  • Platelet count over 75,000.
  • Neutrophil count over 1,000 per microliter.
  • Heart function with an ejection fraction over 50%.
  • Kidney function with creatinine clearance of at least 30 ml/min.
  • Liver enzymes and bilirubin within specified limits.
• Have measurable disease that requires treatment, such as:
  • Serum M protein of at least 0.5 g/dL.
  • Urine M protein of at least 200 mg/24 hours.
  • Abnormal serum free light chain levels.
• If previously had a stem cell transplant, must be fully recovered and more than 60 days post-transplant.
• Willing to have a bone marrow biopsy if needed.
• Life expectancy of at least 6 months.
• Women and men must use effective birth control methods during the study and for a specified time after.

Exclusion Criteria

• Have a type of multiple myeloma that does not produce enough protein to measure.
• Have plasma cell leukemia or amyloidosis.
• Have cancer that has spread to the brain.
• Are pregnant or breastfeeding.
• Have a severe or active infection or fever within a week of starting the study.
• Have had allergic reactions to Carfilzomib or similar drugs.
• Have had a bone marrow or organ transplant.
• Have serious heart problems or other significant health issues that could interfere with the study.
• Have been on experimental treatments within 12 weeks before joining the study.
• Have had problems with proteasome inhibitors like Carfilzomib in the past.
• Are considered unfit for the study by the investigator.